Introduction
Thyroid hormone resistance (THR),' first recognized by Refetoffet al. ( 1 ) , is a syndrome characterized by decreased responsiveness of target tissues to thyroid hormone. Although THR was initially separated into three disorders (generalized resistance to thyroid hormone, selective pituitary resistance, and peripheral resistance to thyroid hormone), it is now thought that these three forms are not distinct but rather are part of a spectrum of resistance (2) . Even within the same kindred, marked heterogeneity in the degree of resistance exists (2, 3) . Most cases of thyroid hormone resistance have evidence of both pituitary and peripheral resistance and exhibit an autosomal dominant mode of inheritance. As a result, thyroid hormone resistance is phenotypically characterized by an inappropriately high thyroid-stimulating hormone (TSH) level and tissue resistance in the presence of high levels of thyroid hormone. Affected members with THR commonly have attention deficit hyperactivity disorder (4, 5) , and language difficulty ( 3 ) and less frequently have short stature and/or delayed bone maturation ( 1, 3, (5) (6) (7) .
Genetic analysis of the thyroid hormone receptor has provided the basis for further understanding syndromes ofthyroid hormone resistance. Two genes, a (8) and d (9) , each ofwhich codes for two alternatively spliced forms of the thyroid hormone receptor, designated al, a2 ( 10), ( 1, and (32 ( 1 ) , have been identified. The a 1, (1, and (32 forms bind thyroid hormone, whereas the a2 does not. The relative roles of various forms of the receptor in mediating thyroid hormone action in different tissues is not presently known.
Initial studies by Usala et al. ( 12) that linked the hTRB gene to THR have led to the identification of more than 30 mutations in the hTR (3 gene (3, 5, 13) . These mutations are primarily clustered in two areas, the T / dimerization domain of exon 9 and the L2 subdomain of exon 10 in the T3-binding region.
One ofthe most interesting aspects ofthe THR is the diversity of phenotypic expression within and among affected members of kindreds (3, 6) . Several mechanisms might account for this phenotypic variability, such as differing levels of the hTRa 1 receptor and a2, differences in the interaction with accessory proteins (14) (15) (16) , and varying ratios of mutant and normal alleles. However, no data currently exist to support any ofthese hypotheses in tissues of patients with thyroid hormone resistance.
In this study, we investigated using an allele specific primer extension method ( 17, 18) whether the differential expression of mutant and normal mRNA levels can explain the phenotypic heterogeneity in a kindred with THR. We measured the mutant and normal mRNA levels in two kindreds: A-H, who has a C to A mutation at codon 448, which results in a histidine for proline substitution, and kindred N-N, whose mutation in exon 9 changes a glycine to glutamate. Both ofthese mutations caused significant decreases in the T3 binding of the hTR (3 receptor ( 19) . While N-N has not been tested, the A-H mutant receptor is known to have a dominant-negative effect in cells cotransfected with mutant, wild type and reporter plasmids (20) . Our data suggest that varying degrees of bone resistance in certain patients with THR may be due at least in part to the differential expression of mutant and wild type hTR3 receptors.
Methods
Informed consent was obtained from members of kindreds A-H and N-N ( Fig. I ) entering a peer review clinical center protocol. The clinical parameters and criteria to assess tissue responsiveness to thyroid hormone have been described elsewhere (5) . Bone age delay of greater than 2 yr assessed at two different times was necessary for diagnosing bone resistance. Bone resistance has been defined as follows in these two kindreds: + (mild), the presence of bone age delay; ++, the presence of bone age delay and within the 5th to 10th percentile in height; +++, the presence ofbone age delay and less than the 5th percentile of height.
Cells. Fibroblasts obtained from a skin biopsy were grown in 10% fetal calf serum and minimal essential media. Except for experiments in which the effect ofpassage on the mutant-to-wild-type ratio in A-H 1 and A-H6 was analyzed, the fibroblasts were frozen between the 3rd and 4th passages. The cells ofthe patients were then thawed and grown in parallel. RNA analyses were performed on cells between the 6th and 10th passages. When the cells reached 80% confluency in a 75 cm2 flask, they were washed with phosphate buffer saline. After washing the fibroblasts with phosphate buffer saline, the RNA was processed by the RNAzol protocol (Cinna Co., Friendswood, TX).
Preparation of cDNA from fibroblasts. 1 gg of total RNA was reverse transcribed with Avian reverse transcriptase using primer A (ATGAGAATGAATCCAGTCAG; 1692-1673) for 1 h. The single stranded cDNA was then amplified with primers A and K (GAGCTG-CCATGTGAAGACCAG; 1168-1188). The product was then reamplified using internal primers H(CAGTCTAATCCTCGAACAC; 1675-1656) and N(GTCCCTTCGCGCTGCTGTG; 1224-1242). The product was analyzed on a 3% agarose gel (Nusieve; FMC Corp, Rockland, ME) and then purified with prep-a-gene (Bio Rad Labs, Hercules, CA). Amplification and reamplification occurred during 35 and 26 cycles, respectively (1 min, 94"C; 1 min, 60'C; and 1 min, 720C).
Allele specific primer extension method. We chose the allele specific primer extension method because of its ease and reliability. We followed the protocol of Driscoll et al. ( 17) and Tennyson et al. ( 18 ) . In brief, 3 ul of amplified cDNA (50 ng), 2 tl of 5X annealing buffer (United States Biochem. Corp., Cleveland, OH) and 1 tL end-labeled primer (GAATGCCCCACAGAACTCTT; 1617-1637) specific for both mutant and wild-type cDNAs were denatured and reannealed slowly. After the temperature cooled to 420C, sequenase 2.0 (United States Biochem. Corp.) and dT, dC, dG at a final concentration of 0.1 mM and 0.25 mM ddA were added for 10 min before formamide was added. With the mutant allele of kindred A-H, the primer is extended just 4 additional bases, whereas with the wild-type cDNA, the primer is extended 18 bases. The primer, wild type, and mutant fragments were then separated on a 17% denaturing acrylamide gel. wild type bands were quantitated by a Beta scanner (AMBIS Inc. San Diego, CA).
Results
We investigated whether the primer extension method could reliably quantitate different amounts of mutant and wild type plasmid DNA after mixing and amplifying different ratios. Fig.  2 reveals that the allele specific primer extension method is extremely sensitive and accurate. Fig. 2 B shows the relationship between the relative ratio of mutant and the wild-type plasmid added. The correlation coefficient is 0.99. After determining that allele specific primer extension was a precise and accurate method and could detect small differences in the mutant and wild-type DNA, we initially isolated RNA from three members of the A-H kindred. The one unaffected member (A-H3), as expected, had only wild type cDNA while the affected members (A-H 1, A-H6) had marked differences in the relative expression of mutant and normal mRNA that were reproducible in several determinations (Fig. 3) . mal hTR/# mRNAs that were nearly equal, 5-yr-old A-H6 had a mutant mRNA level that accounted for 84% of the hTR,3 mRNA. Furthermore, these results were not dependent on the primers since different oligonucleotides used for reverse transcription and amplification gave similar percentages for these three members, and A-H 1 and A-H6 who had the same mutation gave reproducible but different results.
Of the several clinical parameters that were used to stratify patients with generalized resistance to thyroid hormone, only bone resistance was significantly greater in A-H6 compared with A-H 1 at the time the biopsy was performed (Tables I, II ).
The 5-yr-old A-H6's height was less than the 5th percentile whereas the 12-yr-old A-H 1 was in the 40th percentile.
In the six years since we had performed the initial skin biopsy on A-H6, her growth curve had changed significantly from less than the 5th percentile to the 25th percentile ( Fig. 4 ). There had been no significant illness, nutritional deficiencies, nor any evidence ofprecocious puberty to account for the alteration in A-H6's growth curve. Furthermore, since her thyroid hormone therapy was begun two years prior to her growth curve acceleration, it is doubtful that it had a significant role in her growth curve changing from the 5th to 25th percentile. To investigate whether this change might be associated with a relative decrease in the mutant/normal mRNA ratio and presumably the protein levels, we performed a second biopsy on A-H6 when she was 11 yr old. Her mutant-to-normal ratio had de- creased to 67% whereas A-H l's mutant-to-normal ratio was still nearly equal (Table II) . We also analyzed whether the fibroblast passage of A-H6 resulted in a change in the ratio of hTRJ3 gene, and found that passages 1 and 6 displayed similar mutant-to-normal ratios (Fig. 5 ).
Since growth appeared to correlate with differing ratios of hTRI3 gene and presumably the hTR/3 receptor protein, we measured the hTRf mRNA ratios in an additional two affected children of the A-H kindred, A-H4 and A-H8. 3-yr-old A-H8 had a relative mutant hTRfl expression of 52% and never had any evidence ofbone age delay (Fig. 6 ). In contrast, the relative expression ofthe mutant hTRI3 ofthe 13-yr-old A-H4 was 69% (Fig. 6 ). Similar to A-H6, A-H4 at an early age was less than the 5th percentile in height and had a significant bone age delay, but when she was 13 yr old, her height was slightly greater than the 25th percentile. Furthermore, members of kindred N-N who varied little from the expected 50% ofthe mutant and wild-type mRNA did not have any bone resistance. Wild-Type --Mutant -. Primer --
Discussion
The clinical presentation of THR kindreds is quite varied. Although attention deficit hyperactivity disorder is quite common (4), language (3) and bone resistance (3, 5) are less commonly seen. In fact, ofthe 14 kindreds in which we identified a mutation, only four have evidence of bone resistance. Unlike the kindred (first described by Refetoffet al.) who had stippled epiphyses, none of our kindreds exhibited this abnormality. Our kindreds had either bone age delay and/or short stature. Of the four kindreds (3, 5-7) with bone resistance, kindred A-H was particularly interesting in that several members manifested varying degrees of bone resistance.
In this study, we found marked differential expression of mutant and normal mRNA levels in kindred A-H, and this may account for the differing degrees ofbone resistance seen in members within these kindreds. The approximately 20% reduction in the mutant hTRfl mRNA, and presumably the mutant receptor protein, of A-H6 was associated with a marked increase in her height; this amount of mRNA diminution is probably significant in this autosomal dominant disease. Although a correlation was seen between bone resistance and the percent mutant hTRf3 gene expressed in fibroblasts (Table II) , the etiology and molecular mechanisms underlying this relationship remain unclear. Since our clinical parameters for thyroid hormone resistance reflect only a limited number of tissues, it is certainly possible that altered ratios of wild-type and mutant hTRf3 mRNA may be occurring in several tissues not measured by our present clinical parameters. Alternatively, even in tissues where the degree of resistance was measured with clinical parameters, there may be other factors that influence the resistance phenotype of these tissues. Some of the factors that could influence phenotypic features besides an altered ratio are differences in the thyroid hormone alpha and beta receptor levels or RXRf3 levels, but these remain to be elucidated.
The mechanism resulting in the relative increase ofthe mutant allele in the coding region is unknown. Epigenetic factors (21, 22 ) are known to increase or decrease the transcriptional activity of a particular allele and may play a role in the increased transcriptional activity of the mutant allele. Although GRTH is an autosomal dominant disease with the affected allele identified in the two presently studied kindreds, this does not preclude the possibility that the wild-type allelic mRNA level is decreased. Variably expressed wild-type alleles have been found to have significant effects when combined with an affected allele. For instance, Kadowaki et al. (23) report that in one case of leprechaunism, an autosomal recessive disease associated with extreme insulin resistance, a maternally inherited 1 2 3 4 5 6 7 Figure 5 . ";normal" allele is profoundly decreased. Although a mutation has not yet been located in the maternal insulin gene, it is very likely. Alternatively, a preferential increase of the mutant allelic mRNA may occur as a result of increased stability of the mutant mRNA. Mutations in the coding region are known to affect the stability of the mRNA. Both c-fos (24) and # tubulin (25) have areas within the coding region that stabilize these genes. Interestingly, Cohen et al. (26) reported that a mutation in the intron of the oncogene, h-ras, increased its expression by 10-fold. The mechanism causing this increase is also unknown. Perhaps the mutation in kindred A-H increases stability by altering a region that is recognized by a specific nuclease. Because varying levels of mutant and normal hTR# mRNA are present within members of kindred A-H, this mutation would be necessary but not sufficient for these heterogeneous levels of mRNA. A second factor present to differing degrees in affected members of A-H would be necessary to destabilize the normal allele but not the affected allele.
Diversity of phenotypic expression between affected members of kindreds is one of the most interesting aspects of this disease. In addition to the differential expression of the mutant and wild-type alleles, other mechanisms may account for the heterogeneity of clinical manifestations. This diversity of phenotypic expression may reflect varying levels of hTRa in these tissues. Alternatively, transcriptional factors such as RXR that modulate the action of the hTRl ( 14, 15 ) may explain this diversity. We are presently studying the role of these accessory factors in the phenotypic expression of THR.
